Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CSK | P41240 | 1/20 | 0.39 |
| ▸ | GRB2 | P62993 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20950943 | 1.00 | CYP1A2 (0.40) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL20951504 | 0.85 | CTSS (0.46) | TSHRGRB2 | |
| SCHEMBL20951507 | 0.85 | CTSS (0.46) | TSHRGRB2 | |
| SCHEMBL20951916 | 0.84 | GAA (0.41) | CSKGRB2MEN1KMT2ASLC7A5 | |
| SCHEMBL20951915 | 0.84 | GAA (0.41) | CSKGRB2MEN1KMT2ASLC7A5 | |
| SCHEMBL29531634 | 0.75 | SLC7A5 (0.57) | SLC7A5OPRK1 | |
| SCHEMBL23943305 | 0.73 | GRB2 (0.41) | CSKGRB2SLC7A5CTSC | |
| SCHEMBL16836902 | 0.73 | BACE1 (0.56) | CYP1A2CYP2D6CYP2C9TSHRCYP2C19 | |
| SCHEMBL31126251 | 0.73 | CTSK (0.49) | CYP1A2CYP2D6SLC7A5CTSC | |
| SCHEMBL8188747 | 0.73 | CSK (0.45) | CSKSLC7A5CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | TGFB1, TGFB2, SMAD3 | CYP1A2 4871/4885CYP2D6 4857/4885CYP2C9 4860/4885 |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | TGFB1, TGFB2, SMAD3 | CYP1A2 4871/4885CYP2D6 4857/4885CYP2C9 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.